Stockreport

Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]

Aprea Therapeutics, Inc.  (APRE) 
PDF Revenue exceeded analyst estimates by 136%. Earnings per share (EPS) also surpassed analyst estimates by 20%. Looking ahead, revenue is forecast to grow 44% p.a. on a [Read more]